Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 5/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 5/20 | 0.54 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319472 | 0.89 | PIK3CD (0.47) | CARM1PRMT6PRMT8PIK3CDCYP1A2 | |
| SCHEMBL39855 | 0.84 | CARM1 (0.54) | CARM1PRMT6PRMT8PRMT1CYP2C19 | |
| SCHEMBL23823660 | 0.83 | CYP1A2 (0.64) | PIK3CDCYP1A2TDP1SIGMAR1DRD3 | |
| SCHEMBL861660 | 0.82 | CYP2C19 (0.53) | PIK3CDCYP1A2TDP1CYP2C19SIGMAR1 | |
| SCHEMBL11501237 | 0.82 | CARM1 (0.52) | CARM1PRMT6PRMT8PRMT1CYP2C19 | |
| SCHEMBL3947861 | 0.81 | PIK3CD (0.47) | PIK3CDCYP1A2TDP1CYP2C19SIGMAR1 | |
| SCHEMBL12606943 | 0.80 | CARM1 (0.54) | CARM1PRMT6PRMT8PRMT1CYP2C19 | |
| SCHEMBL12510194 | 0.80 | CARM1 (0.54) | CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL1045046 | 0.80 | CARM1 (0.79) | CARM1PRMT6PRMT8PRMT1SIGMAR1 | |
| SCHEMBL240714 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2010-04-29 | — | — | US | claimed |
| EP-2041141-A2 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2009-04-01 | — | — | EP | claimed |
| WO-2008006883-A2 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2008-01-17 | — | — | WO | claimed |
| US-11914248-B2 | Photo-alignment copolymer, photo-alignment film, and optical laminate | FUJIFILM CORPORATION (JP) | 2024-02-27 | — | — | US | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-20230213695-A1 | LAMINATES, POLARIZING PLATES, AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230217789-A1 | OPTICAL LAMINATE AND IMAGE DISPLAY DEVICE | FUJIFILM CORPORATION (JP) | 2023-07-06 | — | — | US | disclosed |
| US-11635558-B2 | Optical laminate and image display device | FUJIFILM CORPORATION (JP) | 2023-04-25 | — | — | US | disclosed |
| WO-2022255764-A1 | NOVEL OXAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR PREVENTION OR TREATMENT OF ALLERGIC DISEASE | 주식회사 에즈큐리스 | 2022-12-08 | — | — | WO | disclosed |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2022-06-07 | — | — | US | disclosed |
| EP-3640248-A1 | AMINOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Beijing Adamadle Biotechnology Limited Liability Company (CN) | 2020-04-22 | — | — | EP | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2010-04-29 | — | — | US | disclosed |
| WO-2009114870-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114874-A2 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| EP-2041141-A2 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006883-A2 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2008-01-17 | — | — | WO | disclosed |
| US-20070037739-A1 | Compounds useful in coating stents to prevent and treat stenosis and restenosis | MEDLOGICS DEVICE CORPORATION (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037739-A1 | Compounds useful in coating stents to prevent and treat stenosis and restenosis | MEDLOGICS DEVICE CORPORATION (US) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | CARM1 1053/4885PRMT6 808/4885PRMT8 843/4885 |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | MTOR, PDPK1, PIKFYVE | CARM1 1779/4885PRMT6 1421/4885PRMT8 1529/4885 |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | BAX, BCL2, BAD | CARM1 1315/4885PRMT6 1631/4885PRMT8 2129/4885 |
| US-11352352-B2 | Aminopyrimidine compound, preparation method therefor and use thereof | WEE1, WEE2, EGFR | CARM1 3865/4885PRMT6 953/4885PRMT8 712/4885 |
| US-20070037739-A1 | Compounds useful in coating stents to prevent and treat stenosis and restenosis | CAD, DBNL, DCAF15 | CARM1 367/4885PRMT6 377/4885PRMT8 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.